ライフサイエンスコーパス: papillary thyroid cancer

1 eptor kinase that undergoes rearrangement in papillary thyroid cancer).

2 ancer, and 29 with the follicular variant of papillary thyroid cancer).

3 st 4 decades, driven largely by increases in papillary thyroid cancer.

4 r (95% CI, 1.1%-4.7%) for SEER distant stage papillary thyroid cancer.

5 oid cancer mortality rate for advanced-stage papillary thyroid cancer.

6 afenib in patients with BRAF(V600E)-positive papillary thyroid cancer.

7 The most frequent association is noted with papillary thyroid cancer.

8 od markedly increases the risk of developing papillary thyroid cancer.

9 ificance of Delphian node (DN) metastasis in papillary thyroid cancer.

10 istent disease in patients with conventional papillary thyroid cancer.

11 istent disease in patients with conventional papillary thyroid cancer.

12 ve of disease-free survival in patients with papillary thyroid cancer.

13 utation is primarily present in conventional papillary thyroid cancer.

14 ay result in a transient increase in risk of papillary thyroid cancer.

15 ary thyroid cancers (MTC) and of a subset of papillary thyroid cancers.

16 e, 3 (20%) were malignant, all of which were papillary thyroid cancers.

17 e lesions were malignant, the majority being papillary thyroid cancers.

18 al rearrangements in a majority of childhood papillary thyroid cancers.

19 action and found frequent CpG methylation in papillary thyroid cancer (23 of 39 patients; 59%) and fo

20 cancer (51.0%) than in follicular variant of papillary thyroid cancer (24.1%) and follicular thyroid

21 AF V600E mutation was higher in conventional papillary thyroid cancer (51.0%) than in follicular vari

22 s, 46% of follicular thyroid cancers, 71% of papillary thyroid cancers, 71% of anaplastic thyroid can

23 s with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid can

24 ne (BRAF V600E), which is primarily found in papillary thyroid cancer and is associated with more agg

25 's thyroiditis is frequently associated with papillary thyroid cancer and may indeed be a risk factor

26 ns of BRAF are found in approximately 45% of papillary thyroid cancers and are enriched in tumors wit

27 urgeons and pathologists in the treatment of papillary thyroid cancer, and especially intermediate-ri

28 erwent thyroid surgery from 2007 to 2009 for papillary thyroid cancer, and had their DN harvested ab

29 010-2013), primarily related to increases in papillary thyroid cancer (annual percent change, 4.4% [9

30 Women with papillary thyroid cancer are at increased risk of in sit

31 l disease risk in patients after surgery for papillary thyroid cancer as a function of primary tumor

32 Four of the lesions were found to be papillary thyroid cancers at fine-needle aspiration biop

33 -based cohort of 10,932 women diagnosed with papillary thyroid cancer between 1988 and 1999.

34 In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associ

35 overshadowed by its more common counterpart-papillary thyroid cancer-despite its unique biological b

36 that prophylactic CLND may be performed for papillary thyroid cancer, especially for advanced tumors

37 Papillary thyroid cancers exhibit a marked increase in s

38 In conclusion, papillary thyroid cancers exhibit specific patterns of a

39 tinct foci of well-differentiated multifocal papillary thyroid cancer from 17 women.

40 unclear whether the increasing incidence of papillary thyroid cancer has been related to thyroid can

41 B-type RAF kinase mutations in papillary thyroid cancer have been found to be associate

42 About half of patients with papillary thyroid cancer have tumours with activating BR

43 ing for an 11-y-old girl with differentiated papillary thyroid cancer, heavy lung involvement, and ce

44 ho were aged 18-64 years when diagnosed with papillary thyroid cancer in 1988-1994 and 574 controls t

45 in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.

46 Papillary thyroid cancer incidence increased for all SEE

47 he key role of TSH signaling in Braf-induced papillary thyroid cancer initiation and provide experime

48 The gene (or genes) for familial papillary thyroid cancer is yet to be identified, wherea

49 The adequacy of unilateral surgery for papillary thyroid cancers is controversial.

50 ed in G(1) arrest in two well differentiated papillary thyroid cancer lines (PTCs) and both G(1) arre

51 of a cohort of 262 patients (66% women, 93% papillary thyroid cancer; median dose, 5,217 MBq [141 mC

52 noted in a gastrointestinal stromal tumour, papillary thyroid cancers, non-small-cell lung cancer, o

53 idual tumor foci in patients with multifocal papillary thyroid cancer often arise as independent tumo

54 The ret/ptc2 papillary thyroid cancer oncogene, an oncogenic form of

55 All papillary thyroid cancer patients with tumor size of 1 c

56 Occult and manifest papillary thyroid cancers present at about the same time

57 Patients with papillary thyroid cancers presenting as occult papillary

58 mutated gene in malignant melanoma (MM) and papillary thyroid cancer (PTC) and is causally involved

59 d most frequent target region for metastatic papillary thyroid cancer (PTC) and medullary thyroid can

60 PURPOSE OF REVIEW: Aggressive variants of papillary thyroid cancer (PTC) have been recognized with

61 ctive iodine (RAI) treatment for early-stage papillary thyroid cancer (PTC) is complex because of unc

62 The incidence of human papillary thyroid cancer (PTC) is increasing and an aggr

63 Papillary thyroid cancer (PTC) rates continue to increas

64 shown to be highly associated with increased papillary thyroid cancer (PTC) risk with an odds ratio o

65 Papillary thyroid cancer (PTC) was diagnosed in 97% of p

66 lysed a multi-generation CS-like family with papillary thyroid cancer (PTC), applying a combined link

67 BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-rela

68 ty risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this is gene

69 vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II

70 nsidered to play a unique prognostic role in papillary thyroid cancer (PTC), with a distinct staging

71 ells (MSCs) in non-carcinogenic thyroids and papillary thyroid cancer (PTC).

72 E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC).

73 on of a murine model of Braf(V600E) -induced papillary thyroid cancer (PTC).

74 E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC).

75 mens for preoperative risk stratification in papillary thyroid cancer (PTC).

76 RET gene are common in radiation-associated papillary thyroid cancer (PTC).

77 only in patients age 45 years or older with papillary thyroid cancer (PTC); patients younger than ag

78 rs including 15 follicular adenomas (FA), 13 papillary thyroid cancers (PTC) and 14 follicular thyroi

79 Papillary thyroid cancers (PTC) are associated with nono

80 The extent of surgery for papillary thyroid cancers (PTC) remains controversial.

81 ten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to

82 E) mutation is found in approximately 40% of papillary thyroid cancers (PTC).

83 he Cancer Genome Atlas study (TCGA study) of papillary thyroid cancers (PTC).

84 pression of oncogenic BRAF (Tg-Braf) develop papillary thyroid cancers (PTCs) that are locally invasi

85 id adenomas, follicular thyroid cancers, and papillary thyroid cancers (PTCs).

86 ients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodin

87 ologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodin

88 Papillary thyroid cancer-specific mortality for cases wi

89 Results: Papillary thyroid cancer-specific mortality occurred in

90 Papillary thyroid cancer-specific mortality occurred in

91 Two individuals had papillary thyroid cancers (stage II and stage III) and o

92 ent, and a long noncoding RNA (lncRNA) gene, papillary thyroid cancer susceptibility candidate 2 (PTC

93 lexity was observed from well-differentiated papillary thyroid cancer to poorly differentiated and an

94 sence of MSCs with a fibrotic fingerprint in papillary thyroid cancer tumors and the autocrine-paracr

95 iagnosed with thyroid cancer from 1974-2013, papillary thyroid cancer was the most common histologic

96 oidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accrued.

97 attributable to an increase in incidence of papillary thyroid cancer, which increased from 2.7 to 7.

98 t patients diagnosed with localized >/= 1-cm papillary thyroid cancer who underwent thyroidectomy wit

99 Patients who undergo surgery for papillary thyroid cancer with only a limited lymph node

100 hyroiditis report an increased prevalence of papillary thyroid cancer, with a favorable disease profi